IX BiopharmaW260718(HQXW) Stock Prices, News, Quotes and Charts

0.128
-0.006-4.48%

10min DelayMarket Closed Jan 16 16:53 CST

113.07MMarket Cap0.00P/E (TTM)

HQXW IX BiopharmaW260718

Quarterly+Annual

YOY

Hide blank lines

(FY)Jun 30, 2025

(FY)Jun 30, 2024

(FY)Jun 30, 2023

(FY)Jun 30, 2022

(FY)Jun 30, 2021

(FY)Jun 30, 2020

(Q2)Dec 31, 2019

(Q1)Sep 30, 2019

(FY)Jun 30, 2019

(Q4)Jun 30, 2019

Total revenue

30.34%7.77M

0.78%5.96M

-58.91%5.91M

724.64%14.39M

77.16%1.75M

46.80%985K

62.62%174K

18.81%120K

172.76%671K

-92.21%129K

Cost of revenue

16.62%5.73M

36.68%4.91M

71.10%3.59M

-1.27%2.1M

35.31%2.13M

31.00%1.57M

125.68%334K

74.02%355K

143.41%1.2M

-76.95%343K

Gross profit

94.66%2.04M

-54.83%1.05M

-81.12%2.32M

3,317.28%12.29M

34.92%-382K

-10.96%-587K

-290.24%-160K

-128.16%-235K

-114.17%-529K

-228.14%-214K

Operating expense

2.01%8.09M

-26.13%7.93M

-2.89%10.73M

13.95%11.05M

-7.19%9.7M

-8.24%10.45M

-11.20%2.8M

-10.95%2.72M

-19.83%11.39M

-56.30%2.42M

Selling and administrative expenses

-0.31%6.69M

-25.85%6.71M

-4.37%9.04M

13.94%9.46M

-3.54%8.3M

9.69%8.61M

4.69%2.28M

19.38%2.01M

6.09%7.85M

-16.14%1.87M

-Selling and marketing expense

-18.07%2M

-23.13%2.44M

52.96%3.17M

-7.74%2.08M

-0.44%2.25M

11.61%2.26M

-9.35%543K

55.77%648K

19.69%2.02M

-2.58%566K

-General and administrative expense

9.85%4.69M

-27.33%4.27M

-20.48%5.87M

22.00%7.38M

-4.65%6.05M

9.02%6.35M

10.03%1.73M

7.42%1.36M

2.05%5.82M

-20.94%1.3M

Research and development costs

-5.20%1.64M

-38.65%1.73M

20.93%2.82M

-15.11%2.33M

9.92%2.75M

-33.63%2.5M

-46.57%522K

-48.04%715K

-53.12%3.77M

-76.48%780K

Total other operating income

-53.05%239K

-55.08%509K

53.32%1.13M

-45.26%739K

105.79%1.35M

192.86%656K

----

-81.70%224K

----

Operating profit

12.11%-6.05M

18.21%-6.88M

-778.31%-8.41M

112.30%1.24M

8.66%-10.08M

7.39%-11.04M

7.33%-2.96M

6.42%-2.96M

17.54%-11.92M

50.96%-2.64M

Net non-operating interest income expense

25.92%-303K

-54.92%-409K

-30.69%-264K

-20.96%-202K

-10.60%-167K

-297.37%-151K

6.56%-57K

-3.33%-62K

-40.74%-38K

310.61%139K

Non-operating interest income

-45.45%18K

371.43%33K

--7K

--0

-91.95%7K

-55.15%87K

----

-13.00%194K

----

Non-operating interest expense

-27.38%321K

63.10%442K

34.16%271K

16.09%202K

-26.89%174K

2.59%238K

-6.56%57K

3.33%62K

-7.20%232K

-16.67%55K

Net investment income

-4,573.68%-3.4M

102.74%76K

-45.11%-2.77M

-206.46%-1.91M

367.45%1.8M

123.19%384K

-52.63%-1.66M

Gain/Loss on financial instruments designated as cash flow hedges

Gain/Loss on derecognition of available-for-sale financial assets

99.80%-5K

-244.14%-2.51M

153.45%1.74M

-3.26M

Income from associates and other participating interests

Special income /charges

-107K

Less:Write off

--0

--107K

--0

----

Other non-operating income /expenses

-149.03%-386K

-155K

-84.86%33K

-28.05%218K

-11.14%303K

277.61%595K

-148.09%-325K

4.60%341K

-38.23%677K

Income before tax

-1.55%-10.14M

-2.87%-9.99M

-136.79%-9.71M

50.21%-4.1M

21.58%-8.23M

20.87%-10.5M

32.55%-2.42M

0.21%-3.35M

12.91%-13.27M

19.99%-3.48M

Income tax

-99.88%1K

989.01%809K

-118.24%-91K

49,800.00%499K

-142.31%-22K

-51.72%14K

Net income

6.05%-10.14M

-12.26%-10.79M

-109.11%-9.62M

44.16%-4.6M

21.57%-8.23M

-251.02%-10.5M

32.82%-2.42M

-3.21%-3.35M

80.18%-2.99M

13.79%-3.77M

Net income continuous operations

6.05%-10.14M

-12.26%-10.79M

-109.11%-9.62M

44.16%-4.6M

21.57%-8.23M

20.74%-10.5M

32.23%-2.42M

0.21%-3.35M

13.35%-13.25M

20.20%-3.49M

Net income discontinuous operations

----

--0

5,213.47%10.26M

---280K

Noncontrolling interests

Net income attributable to the company

6.05%-10.14M

-12.26%-10.79M

-109.11%-9.62M

44.16%-4.6M

21.57%-8.23M

-251.02%-10.5M

32.82%-2.42M

-3.21%-3.35M

80.18%-2.99M

13.79%-3.77M

Preferred stock dividends

Other under preferred stock dividend

Net income attributable to common stockholders

6.05%-10.14M

-12.26%-10.79M

-109.11%-9.62M

44.16%-4.6M

21.57%-8.23M

-251.02%-10.5M

32.82%-2.42M

-3.21%-3.35M

80.18%-2.99M

13.79%-3.77M

Gross dividend payment

Basic earnings per share

Diluted earnings per share

Dividend per share

Currency Unit

SGD

	(FY)Jun 30, 2025	(FY)Jun 30, 2024	(FY)Jun 30, 2023	(FY)Jun 30, 2022	(FY)Jun 30, 2021	(FY)Jun 30, 2020	(Q2)Dec 31, 2019	(Q1)Sep 30, 2019	(FY)Jun 30, 2019	(Q4)Jun 30, 2019
Total revenue	30.34%7.77M	0.78%5.96M	-58.91%5.91M	724.64%14.39M	77.16%1.75M	46.80%985K	62.62%174K	18.81%120K	172.76%671K	-92.21%129K
Cost of revenue	16.62%5.73M	36.68%4.91M	71.10%3.59M	-1.27%2.1M	35.31%2.13M	31.00%1.57M	125.68%334K	74.02%355K	143.41%1.2M	-76.95%343K
Gross profit	94.66%2.04M	-54.83%1.05M	-81.12%2.32M	3,317.28%12.29M	34.92%-382K	-10.96%-587K	-290.24%-160K	-128.16%-235K	-114.17%-529K	-228.14%-214K
Operating expense	2.01%8.09M	-26.13%7.93M	-2.89%10.73M	13.95%11.05M	-7.19%9.7M	-8.24%10.45M	-11.20%2.8M	-10.95%2.72M	-19.83%11.39M	-56.30%2.42M
Selling and administrative expenses	-0.31%6.69M	-25.85%6.71M	-4.37%9.04M	13.94%9.46M	-3.54%8.3M	9.69%8.61M	4.69%2.28M	19.38%2.01M	6.09%7.85M	-16.14%1.87M
-Selling and marketing expense	-18.07%2M	-23.13%2.44M	52.96%3.17M	-7.74%2.08M	-0.44%2.25M	11.61%2.26M	-9.35%543K	55.77%648K	19.69%2.02M	-2.58%566K
-General and administrative expense	9.85%4.69M	-27.33%4.27M	-20.48%5.87M	22.00%7.38M	-4.65%6.05M	9.02%6.35M	10.03%1.73M	7.42%1.36M	2.05%5.82M	-20.94%1.3M
Research and development costs	-5.20%1.64M	-38.65%1.73M	20.93%2.82M	-15.11%2.33M	9.92%2.75M	-33.63%2.5M	-46.57%522K	-48.04%715K	-53.12%3.77M	-76.48%780K
Total other operating income	-53.05%239K	-55.08%509K	53.32%1.13M	-45.26%739K	105.79%1.35M	192.86%656K	----	----	-81.70%224K	----
Operating profit	12.11%-6.05M	18.21%-6.88M	-778.31%-8.41M	112.30%1.24M	8.66%-10.08M	7.39%-11.04M	7.33%-2.96M	6.42%-2.96M	17.54%-11.92M	50.96%-2.64M
Net non-operating interest income expense	25.92%-303K	-54.92%-409K	-30.69%-264K	-20.96%-202K	-10.60%-167K	-297.37%-151K	6.56%-57K	-3.33%-62K	-40.74%-38K	310.61%139K
Non-operating interest income	-45.45%18K	371.43%33K	--7K	--0	-91.95%7K	-55.15%87K	----	----	-13.00%194K	----
Non-operating interest expense	-27.38%321K	63.10%442K	34.16%271K	16.09%202K	-26.89%174K	2.59%238K	-6.56%57K	3.33%62K	-7.20%232K	-16.67%55K
Net investment income	-4,573.68%-3.4M	102.74%76K	-45.11%-2.77M	-206.46%-1.91M	367.45%1.8M	123.19%384K			-52.63%-1.66M
Gain/Loss on financial instruments designated as cash flow hedges
Gain/Loss on derecognition of available-for-sale financial assets	99.80%-5K	-244.14%-2.51M	153.45%1.74M	-3.26M	0
Income from associates and other participating interests
Special income /charges	0	-107K	0
Less:Write off	--0	--107K	--0	----	----	----	----	----	----	----
Other non-operating income /expenses	-149.03%-386K	-155K		-84.86%33K	-28.05%218K	-11.14%303K	277.61%595K	-148.09%-325K	4.60%341K	-38.23%677K
Income before tax	-1.55%-10.14M	-2.87%-9.99M	-136.79%-9.71M	50.21%-4.1M	21.58%-8.23M	20.87%-10.5M	32.55%-2.42M	0.21%-3.35M	12.91%-13.27M	19.99%-3.48M
Income tax	-99.88%1K	989.01%809K	-118.24%-91K	49,800.00%499K	1K	0	0	0	-142.31%-22K	-51.72%14K
Net income	6.05%-10.14M	-12.26%-10.79M	-109.11%-9.62M	44.16%-4.6M	21.57%-8.23M	-251.02%-10.5M	32.82%-2.42M	-3.21%-3.35M	80.18%-2.99M	13.79%-3.77M
Net income continuous operations	6.05%-10.14M	-12.26%-10.79M	-109.11%-9.62M	44.16%-4.6M	21.57%-8.23M	20.74%-10.5M	32.23%-2.42M	0.21%-3.35M	13.35%-13.25M	20.20%-3.49M
Net income discontinuous operations	----	----	----	----	----	----	--0	--0	5,213.47%10.26M	---280K
Noncontrolling interests
Net income attributable to the company	6.05%-10.14M	-12.26%-10.79M	-109.11%-9.62M	44.16%-4.6M	21.57%-8.23M	-251.02%-10.5M	32.82%-2.42M	-3.21%-3.35M	80.18%-2.99M	13.79%-3.77M
Preferred stock dividends
Other under preferred stock dividend	0	0	0	0	0	0	0	0	0	0
Net income attributable to common stockholders	6.05%-10.14M	-12.26%-10.79M	-109.11%-9.62M	44.16%-4.6M	21.57%-8.23M	-251.02%-10.5M	32.82%-2.42M	-3.21%-3.35M	80.18%-2.99M	13.79%-3.77M
Gross dividend payment
Basic earnings per share
Diluted earnings per share
Dividend per share
Currency Unit	SGD	SGD	SGD	SGD	SGD	SGD	SGD	SGD	SGD	SGD

China and the United States have successively adjusted multiple tariff and non-tariff measures, beginning to implement the consensus outcome Show More

牛牛課堂

Oct 13, 2025 18:05

[Opportunity Express] The US-China rivalry escalates! The rare earth industry becomes a "game-changer." How should investors respond?

Food流油

Apr 14, 2025 15:43

"Leaving the Group - Raising Taxes - Tweeting: The 'Money Making Strategy' of the Most Wild Gemini in Contemporary Times"

IX BiopharmaW260718 (HQXW)

HQXW IX BiopharmaW260718